DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for oophoritis — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOophoritis maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for oophoritis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Clinical and immunological types of course of chronic salpingoophoritis
AbstractIn the article the problem of clinical and immunological characteristic of chronic salpingo-oophoritis is observed. 21 patients with chronic salpingo-oophoritis were investigated. The patients from the 1 group (n=11) had slight form of salpingo-oophoritis. The patients from the 2 group (n=10) had hard form of salpingo-oophoritis. Clinical and immunological parameters were determined. The patients with different clinical characteristic had different immunological parameters. To improve the results of treatment of chronic salpingo-oophoritis it is necessary to take into account immunological characteristic.
The importance of combined oral contraceptives use in carrying out rehabilitation actions after contacted salpingo-oophoritis
AbstractIn the following work the result of a non-randomized clinical research in which efficiency and acceptability of Belara® for prophylaxis and treatments of autoimmune oophoritis are presented was estimated. After 6 months of reception of a preparation reduction of the maintenance of the contents of antiovarian antibodies that allows to recommend its use to young patients with PID is ascertained.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
